Jasper Therapeutics, Inc.

JSPR

$0.67

-2.29%

N/A-$0.02

Salud

Biotecnología

NASDAQ

Negociación activa

Jasper Therapeutics, Inc., una empresa de biotecnología en etapa clínica, se centra en el desarrollo de terapias dirigidas a enfermedades impulsadas por ...

Cadena de suministro de JSPR

Aguas arriba

Fundiciones, empaquetado, memoria, obleas, componentes y proveedores de insumos.

Aguas arriba

Lonza Sales AG (Lonza Group)

Symbio Research (Symbio Proinnovera)

Stanford University

National Cancer Institute (NCI) / National Institutes of Health (NIH)

Sartorius AG

Lonza Sales AG (Lonza Group)

SIX:LONN

Contract Manufacturing Organization (CMO) – sole-source manufacturer of briquilimab drug substance and drug product for clinical trials

Amgen Inc.

NASDAQ:AMGN

Licensor – exclusive worldwide license agreement for briquilimab (formerly AMG 191); original discoverer of the antibody

Symbio Research (Symbio Proinnovera)

Contract Research Organization (CRO) – clinical trial management for the Phase 1b/2a BEACON study of briquilimab in CSU

Stanford University

Academic Research Collaborator – clinical collaboration agreement; company co-founded by Stanford professor Dr. Judith Shizuru; foundational research on anti-CD117 conditioning

National Cancer Institute (NCI) / National Institutes of Health (NIH)

Clinical Trial Collaborator – clinical trial agreement for evaluation of briquilimab in AML/MDS stem cell transplant conditioning

Aguas abajo

Clientes, distribuidores, OEM y canales que absorben la producción.

Aguas abajo

None (Pre-Commercial Stage)

Jasper has no approved products and generates no commercial revenue. No downstream customers exist. The company initiated a strategic alternatives review on June 1, 2026, exploring asset sales, licensing, collaborations, or a full company sale.

Comparables

Empresas cotizadas comparables y valores de seguimiento usados como representantes del análisis.

Comparables

Celldex Therapeutics, Inc.

Novartis AG

X4 Pharmaceuticals, Inc.

Celldex Therapeutics, Inc.

NASDAQ:CLDX

Direct competitor also developing an anti-KIT monoclonal antibody (barzolvolimab) for the same CSU/CIndU indications. Both target the c-Kit receptor on mast cells. Celldex is later-stage with Phase 3 data and a strong cash position, serving as the primary public-market comparable.

Novartis AG

NYSE:NVS

Novartis is advancing remibrutinib (oral BTK inhibitor) in CSU and also acquired AVROBIO's gene therapy program which had been collaborating with Jasper. A potential strategic acquirer of Jasper's briquilimab asset given the CSU space overlap.

X4 Pharmaceuticals, Inc.

NASDAQ:X4PH

Clinical-stage biotechnology company with a single pipeline asset and similar risk profile (pre-revenue, cash-constrained, strategic review). Serves as a market-risk proxy for single-asset clinical-stage biotech.

Geografía

Exposiciones regionales que pueden distorsionar la red de suministro.

Geografía

United States (California)

Switzerland (Basel/Visp)

Stanford University

National Cancer Institute (NIH)

Amgen Inc.

Lonza Sales AG

United States (California)

Operational headquarters, clinical trial sites, academic research partners

Stanford UniversityClinical collaboration and foundational research

National Cancer Institute (NIH)Clinical trial collaboration for AML/MDS

Amgen Inc.NASDAQ:AMGNLicense agreement for briquilimab

Switzerland (Basel/Visp)

Single-source drug substance and drug product manufacturing

Lonza Sales AGSIX:LONNSole CMO for briquilimab manufacturing

Concentración

Exposiciones de concentración de clientes, proveedores o socios que pueden distorsionar la red de suministro.

Foundry

Critical

Jasper relies entirely on Lonza as its sole contract manufacturing organization for briquilimab drug substance and drug product. In July 2025, a compromised drug lot from Lonza corrupted BEACON study results, causing a 64.6% stock crash, clinical program delays, and a class action lawsuit. No alternative CMO is qualified.

Other

Critical

Single-asset risk: Jasper's entire pipeline depends on briquilimab. No backup candidates or diversified programs exist. Any clinical or manufacturing setback for briquilimab affects 100% of company value.

Other

Critical

Cash runway risk: As of March 31, 2026, Jasper held only $14.1M in cash. At current burn rate (~$5-6M/quarter), the company has limited runway, triggering the June 2026 strategic alternatives review which could result in sale, wind-down, or dissolution.

Other

High

Class action litigation: Rosen Law Firm and other plaintiffs have filed securities class action lawsuits related to the manufacturing issues and clinical trial disclosure failures.

Customer

Critical

No downstream customers or commercial distribution network exists. The company has no path to revenue without a partnership, licensing deal, or acquisition.

Composición de ingresos

Cómo la composición de ingresos se traduce en apalancamiento y dependencia en la cadena de suministro.

Product Revenue

0.0%

$0.0B

Pre-revenue clinical-stage company. No commercial sales. All supply chain activity is R&D-focused (clinical trial materials, CRO services, drug substance manufacturing for trials).

Research & Development (Operational Spend)

100.0%

All expenditure funds upstream CDMO/CMO services (Lonza for drug substance), CRO services (Symbio for clinical trials), and academic collaborations. $63.1M R&D expense in FY2025.

Sobre nosotrosPolítica de privacidadTérminos de servicioAviso legalDirectorio de accionesETFÍndicesCarteras 13FPrecios objetivoHerramientas gratuitasMapa tecnológicoÚnete a nuestro Slack

Plutux no es un asesor de inversiones. Los datos de mercado y el análisis generado por IA son solo informativos y educativos, no asesoramiento de inversión. Aviso legal

No se encontraron acciones que coincidan

Jasper Therapeutics, Inc.

Cadena de suministro de JSPR

Aguas arriba

Lonza Sales AG (Lonza Group)

Amgen Inc.

Symbio Research (Symbio Proinnovera)

Stanford University

National Cancer Institute (NCI) / National Institutes of Health (NIH)

Thermo Fisher Scientific Inc.

Danaher Corporation (Cytiva)

Sartorius AG

Aguas abajo

None (Pre-Commercial Stage)

Comparables

Celldex Therapeutics, Inc.

Novartis AG

X4 Pharmaceuticals, Inc.

Geografía

United States (California)

Switzerland (Basel/Visp)

Cadena de suministro de JSPR

Aguas arriba

Lonza Sales AG (Lonza Group)

Amgen Inc.

Symbio Research (Symbio Proinnovera)

Stanford University

National Cancer Institute (NCI) / National Institutes of Health (NIH)

Thermo Fisher Scientific Inc.

Danaher Corporation (Cytiva)

Sartorius AG

Aguas abajo

None (Pre-Commercial Stage)

Comparables

Celldex Therapeutics, Inc.

Novartis AG

X4 Pharmaceuticals, Inc.

Geografía

United States (California)

Switzerland (Basel/Visp)